Ipilimumab

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

Also Known As:

Networked: 3324 relevant articles (491 outcomes, 794 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wolchok, Jedd D: 99 articles (10/2022 - 01/2008)
2.	Hodi, F Stephen: 84 articles (10/2022 - 09/2008)
3.	Ascierto, Paolo A: 70 articles (10/2022 - 07/2011)
4.	Robert, Caroline: 58 articles (05/2022 - 08/2010)
5.	Postow, Michael A: 54 articles (05/2022 - 03/2012)
6.	Schadendorf, Dirk: 52 articles (10/2022 - 02/2010)
7.	Larkin, James: 49 articles (10/2022 - 11/2011)
8.	Long, Georgina V: 48 articles (10/2022 - 01/2013)
9.	Maio, Michele: 48 articles (10/2022 - 08/2009)
10.	Hamid, Omid: 45 articles (01/2022 - 12/2007)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 08/01/2021 - "The most cited article (Hodi et al.) demonstrated improved survival with ipilimumab in patients with metastatic melanoma (7894 citations). " 05/01/2015 - "The inhibitory anti-CTLA-4 antibody, ipilimumab, dramatically improved survival in a subgroup of metastatic melanoma patients. " 08/01/2016 - "Ipilimumab has proven to be effective in metastatic melanoma patients. " 01/01/2014 - "Ipilimumab has been shown to improve overall survival in patients with metastatic melanoma; however, complete responses (CRs) are uncommon. " 12/01/2012 - "Outstanding issues include the role of ipilimumab in the adjuvant treatment of patients who are at high risk for relapse, and the optimal treatment sequence for patients with BRAFV600 mutant melanoma, as small-molecule BRAF inhibitors have also been shown to improve the survival for this subgroup of patients."
2.	Neoplasms (Cancer) 12/01/2012 - "Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an expanded access program (EAP) with ipilimumab at its licensed dose of 3 mg/kg illustrate the efficacy of ipilimumab in an expanded access setting and the range of different tumor response patterns encountered. " 10/01/2017 - "Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer." 01/01/2017 - "After four cycles of ipilimumab, there was a complete remission of the disease with no evidence of vital, FDG-positive tumor tissue. " 12/01/2018 - "Within the concurrent ipilimumab group, SRS dose ≥ 20 Gy was associated with significantly greater median tumor volume reduction at 3 months (p = 0.01) and 6 months (p = 0.02). " 07/01/2012 - "Analysis of pre-treatment tumors indicated that patients with high baseline expression levels of immune-related genes were more likely to respond favorably to ipilimumab. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 11/01/2007 - "Therefore, a phase II study of ipilimumab was conducted in patients with metastatic renal cell cancer with a primary end point of response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. " 01/01/2020 - "Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma." 04/14/2015 - "Although ipilimumab has been shown to improve survival in patients with metastatic melanoma and cause regression of metastatic renal cell carcinoma, the associated immune-related toxicities are of concern. " 05/20/2006 - "We treated 198 patients with metastatic melanoma (MM) or renal cell carcinoma (RCC) with ipilimumab. " 01/01/2022 - "We demonstrate the feasibility and positive effect of a prospective patient selection based on tumour molecular phenotype to choose the most efficacious treatment between nivolumab with or without ipilimumab and a VEGFR-TKI in the first-line treatment of metastatic clear-cell renal cell carcinoma. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2017 - "In this study, we investigate specific binding of radiolabeled ipilimumab to CTLA-4 expressed by human non-small cell lung cancer cells in vivo using positron emission tomography (PET). " 11/14/2019 - "Modifying the frequency of ipilimumab dosing may mitigate toxicity rates and positively impact quality of life without compromising efficacy, a hypothesis being explored in other tumour types such as non-small cell lung cancer. " 01/01/2019 - "Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer." 01/01/2016 - "Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer." 12/01/2013 - "An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer."
5.	Brain Neoplasms (Brain Tumor) 03/01/2015 - "CONCLUSIONS In this series, patients who underwent resection of brain metastases in temporal proximity to receiving ipilimumab had qualitatively improved performance status following surgery in most cases. " 01/01/2014 - "However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. " 06/01/2013 - "In this retrospective study, administration of ipilimumab neither increased toxicity nor improved intracerebral disease control in patients with limited brain metastases who received SRS." 01/01/2016 - "This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases." 09/01/2018 - "There is evidence that the combination of ipilimumab and stereotactic radiosurgery (SRS) for brain metastases improves outcomes. "

Related Drugs and Biologics

1.	Nivolumab
2.	pembrolizumab
3.	Immune Checkpoint Inhibitors
4.	Monoclonal Antibodies
5.	Vemurafenib
6.	Sunitinib (Sutent)
7.	CTLA-4 Antigen
8.	Antibodies
9.	Proteins (Proteins, Gene)
10.	Dacarbazine (DIC)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Castration